Mild Alzheimer's leads to errors on driving test

September 13, 2004

ST. PAUL, Minn. - People with mild Alzheimer's disease make more mistakes on a driving test than older people with no cognitive problems, according to a study published in the September 14 issue of Neurology, the scientific journal of the American Academy of Neurology.

The study involved an on-road driving test with 32 people with mild Alzheimer's disease and 136 people with no neurological disorders. The people with Alzheimer's disease were still driving, although some had reduced their driving due to restrictions imposed by themselves or their families.

The 45-minute test included "on-task" time when the drivers were given verbal instructions to follow a route, as well as time when the drivers were not "on task," or were not asked to remember and follow instructions.

The people with Alzheimer's were more likely to make driving errors during the route-following task than those without Alzheimer's. For example, more than 70 percent of the people with Alzheimer's made at least one wrong turn while following the route, while about 20 percent of those without Alzheimer's made at least one wrong turn. And nearly 70 percent of those with Alzheimer's made two or more safety errors, such as erratic steering or going onto the shoulder, while following the route, compared to about 20 percent of those without Alzheimer's.

Performing the task accentuated the safety gap between the two groups compared to when drivers were not asked to follow specific instructions.

"There was no difference in the basic control of the vehicle for the people with Alzheimer's," said study author and neurologist Matthew Rizzo, MD, of the University of Iowa in Iowa City. "This leads us to believe that the mental demands of following verbal instructions and navigating a new route can compete with drivers' cognitive resources and potentially impair their driving abilities."

People with Alzheimer's who were familiar with the area of town where the test was conducted did not get lost during the test, although those with Alzheimer's who were unfamiliar with the area were likely to get lost during the test.

"Drivers with early Alzheimer's may have trouble learning new routes but continue to navigate accurately on familiar routes," Rizzo said. "This suggests that drivers' license policies could be considered that would allow driving only in familiar neighborhoods for people with mild dementia."

Rizzo also noted that some of the people with Alzheimer's did not make any errors or get lost, and drove safely. "This suggests that some people with mild Alzheimer's remain fit drivers and should be allowed to continue to drive," he said.

The study concluded that the driving ability of people with mild cognitive impairment should be assessed with driving tests that include tasks that check their memory and attention skills.

Neurologist David Drachman, MD, of the University of Massachusetts Medical School in Worcester, who wrote a commentary about the study, agreed that on-road evaluation is the best way to test driving competence. He said, "If the driver with mild Alzheimer's is safe today, I recommend that a family member ride with him or her at least once a month, and if the observer feels endangered, the driver should no longer operate a vehicle."

Ergun Uc, MD, Steven Anderson, PhD, Qian Shi, MS, and Jeff Dawson, ScD, also of the University of Iowa, strongly contributed to this study.
-end-
The study was supported by grants from the National Institute on Aging.

The American Academy of Neurology, an association of more than 18,000 neurologists and neuroscience professionals, is dedicated to improving patient care through education and research. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as multiple sclerosis, restless legs syndrome, Alzheimer's disease, narcolepsy, and stroke.

For more information about the American Academy of Neurology, visit its Website at www.aan.com.

American Academy of Neurology

Related Neurology Articles from Brightsurf:

Lancet Neurology publishes results of AFFiRiS' Phase 1 trial with PD01A in Parkinson's
AFFiRiS AG, a clinical-stage biotechnology company developing novel disease-modifying specific active immunotherapies (SAITs), today announced that detailed results of the phase 1 clinical program with its lead candidate PD01 in early Parkinson's disease (PD) patients were published in the peer-reviewed journal The Lancet Neurology

Telemedicine effective for monitoring patients in large pediatric neurology network
As the COVID-19 pandemic sent entire communities into lockdown, doctors quickly adopted telehealth strategies without knowing whether they would be effective or feasible.

The Lancet Neurology: Discovery could speed diagnosis and treatment of children with life-threatening neurological diseases
A group of life-threatening neurological conditions affecting children have been linked to an antibody which points to potential treatment, according to an observational multicentre study involving 535 children with central nervous system (CNS) demyelinating disorders and encephalitis, published in The Lancet Neurology journal.

Meaningful change in culture urged to save neurology, reduce gender gap
UC Davis School of Medicine dean, NINDS deputy director lead national charge to improve conditions for women in neurology.

BrainStorm Cell Tx publishes NurOwn ALS Phase 2 randomized trial data in neurology
Results from Brainstorm Cell Therapeutic's NurOwn randomized Phase 2 clinical trial were published in Neurology.

The Lancet Neurology: Pioneering study suggests that an exoskeleton for tetraplegia could be feasible
A whole-body exoskeleton, operated by recording and decoding brain signals, has helped a tetraplegic patient to move all four of his paralysed limbs, according to results of a 2-year trial published in The Lancet Neurology journal.

The Lancet Neurology: Frailty could make people more susceptible to dementia
New research published in The Lancet Neurology journal suggests that frailty makes older adults more susceptible to Alzheimer's dementia, and moderates the effects of dementia-related brain changes on dementia symptoms.

The Lancet Neurology: Cannabis-based drug in combination with other anti-spasticity
Oral spray containing two compounds derived from the cannabis plant reduced spasticity compared with placebo in patients already taking anti-spasticity drugs.

New neurology studies a 'wakeup call' for global health
Neurology experts from around the world will convene Nov. 27 in New Zealand for a Global Brain Summit examining what one calls 'the greatest challenge of societies in the 21st century.' Among the neurological disorders to be discussed at the Summit are stroke, traumatic brain injury, Alzheimer's disease, Parkinson's disease, multiple sclerosis, and migraine and other headaches.

The Lancet Neurology: Daily and weekly cycles of epileptic seizures more common than previously thought
Understanding the pattern of seizures, and how they are linked to circadian rhythms, could be important in improving management of epilepsy.

Read More: Neurology News and Neurology Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.